© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Nefiracetam's story pulls from Japan's pharmaceutical traditions of the late 1970s and 80s, when researchers kept searching for cognitive enhancers that act on the brain without the heavy baggage of classic stimulants. Scientists at Daiichi Pharmaceutical came up with Nefiracetam while hunting for compounds similar to Piracetam, only with better potency and a broader effect on neurotransmission. It entered the scene at a time curiosity about improving memory and learning was running high, partly because of concerns about rising dementia cases in aging populations. Nefiracetam didn't just arrive as a copy; it marked a step forward by hitting more molecular targets and promising something new for patients and scientists alike. As years passed, its journey meandered through animal studies, clinical trials, limited medical use in some countries, and plenty of debate in research circles about its true potential and safety.
Nefiracetam sits under the broad family of racetam compounds, but it forges its own path. Unlike Piracetam or Aniracetam, it sports a more complex chemical structure that helps it slip through cell membranes more easily and reach the brain with fewer obstacles. Sold as a white, crystalline powder, it often ends up encapsulated for lab use or research. The typical user wouldn’t spot it at a pharmacy counter in North America, since it’s not approved for general medical use, but researchers and nootropic enthusiasts keep it in their sights. Over the years, supplement stores and research suppliers have shipped it under various banners, often labeled strictly “for research purposes only.” Prescribed forms, like those sometimes offered in select Asian markets, carry regulated instructions and more comprehensive labeling—a stark contrast to the wild west feel of the nootropics online marketplace.
Chemically, Nefiracetam is known as N-(2,6-dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)acetamide, or C14H18N2O2 if you want the shorthand. It features a pyrrolidone ring, blending with a dimethylphenyl group that sets it apart from its cousins. This structure gives the compound its lipophilic nature, meaning it blends into fats more easily than water. The melting point sits around 98–100°C, which is considered low in the context of laboratory chemical synthesis. Nefiracetam's solubility leans toward alcohols and certain organic solvents, less so for plain water—one reason researchers handle it with care during solution preparation. Powdered Nefiracetam holds up in airtight containers, stored away from light and humidity, pointing to a respectable chemical stability that matters for both lab work and long-term storage.
Quality equals consistency for compounds like Nefiracetam, especially when dealing with laboratory standards. Most legitimate supplies land in purity ranges above 98%, by HPLC analysis. Labels typically flag the molecular weight—246.31 g/mol—mention recommended storage temperatures (2°C–8°C), and include hazard notes mandated under GHS classification, such as warnings about eye, respiratory, and skin irritation in case of accidental exposure. Data sheets bundle in crucial handling info, proper PPE guidance, and disposal recommendations. If you look at packaging from established lab suppliers, batch numbers, expiration dates, MSDS access, and the name of the manufacturing lab dominate the label. Less reputable sellers skip detail, which makes sourcing from credible suppliers essential for any research operation.
Synthesizing Nefiracetam starts with key aromatic amines and acetic acid derivatives. Chemists work up a reaction cascade where they build the pyrrolidone ring from a lactam synthesis, then couple that with a dimethylphenyl group through acylation strategies. The process tolerates small changes, but the basic template stays the same: generate the core pyrrolidone structure, attach the side chains, purify via recrystallization, and check purity via spectrometry. Consistent yield hinges on reaction temperature, solvent purity, and careful exclusion of moisture—otherwise degradation products and isomers creep in. No commercial synthesis skips the final HPLC and NMR checks for structure and purity. At a large scale, process safety comes into play, since some intermediates release noxious fumes and require full fume hood handling and waste neutralization.
Researchers don’t just take Nefiracetam at face value. Chemical modifications unlock new activity or reduce unwanted side effects, by tweaking the amide group, shifting methyl substitutions on the aromatic ring, or altering the length of the acyl chain. Some studies see structural analogs where the base is maintained, but side chains swap around, hunting for better brain penetration or receptor selectivity. Certain modifications increase binding to GABAergic or cholinergic sites, while others seem to upend activity altogether. In medicinal chemistry, these modifications offer a chance to chase after compounds with less toxicity and clearer medical use, though each change brings its own battery of safety evaluations.
Beyond its IUPAC moniker, Nefiracetam goes by names like DM-9384, NEFIRACETAM, and sometimes N-(2,6-dimethylphenyl)-2-pyrrolidone acetamide. In Japanese clinical research, you’ll see the shorter “Nefiracetam” in product sheets. For chemical catalogues, “DM 9384” or “CAS 77191-36-7” occupies listings. Supplement retailers sometimes dream up trademarked blends or stack it under proprietary names, though purists stick to the single-compound version. Clarity around synonyms protects against mistaken identity in research orders—a lesson you only need to learn once if a shipment of the wrong racetam shows up on your lab bench.
Working with Nefiracetam puts safety at the center, whether you’re handling milligrams in a chemistry lab or performing live animal studies. The powder irritates mucous membranes, so nitrile gloves and safety glasses come standard. Fume hoods remove airborne dust, important given the compound’s small size and ease of inhalation. Chemical spill kits, eyewash stations, and updated SDS sheets stand by at every prep station. In clinical contexts, dosing and observation need strict protocol management since adverse events—though rare—include headaches, nausea, and agitation in some human trials. Long-term exposure effects remain a research subject, so precaution keeps researchers and lab techs from being the subjects of tomorrow’s toxicity papers. Disposal routes for Nefiracetam waste involve incineration through certified chemical disposal, never simple drain or trash methods.
Nefiracetam drives curiosity because its footprint spans multiple areas. In research, scientists use it as a tool to probe neurotransmitter systems, especially for roles in memory formation. Preclinical work shows improved learning and recall in animal models of Alzheimer’s and stroke, making it a hopeful lead for neurodegenerative conditions. Some clinical trials have explored Nefiracetam’s use in treating cognitive deficits caused by cerebrovascular disease, with mixed results depending on patient pool and dosage. Outside of formal medicine, Nefiracetam pulls in attention from the nootropics community, looking for any edge in mental clarity or memory. That interest sprints ahead of regulatory approvals—so the broader medical community urges caution and more data before general use. Properly guided, the compound may hold keys for treating specific memory and cognitive disorders that currently lack effective options.
The road of scientific research on Nefiracetam feels longer than many realize. A heap of early studies used rat and monkey models to trace its impact on synaptic plasticity, long-term potentiation, and neurotransmitter release. These experiments showed promise: increases in acetylcholine, dopamine, serotonin, and GABA signaling were reported, implicating broad neural network involvement. Human trials, though smaller and less frequent, tracked possible benefits for cognitive rehabilitation after stroke or hypoxia. More recent work probes whether Nefiracetam analogs can treat epilepsy, anxiety, or even retinal disorders. Advances in imaging and molecular biology have let researchers study exactly which neurons light up in response, and which protein targets Nefiracetam modifies at nanomolar levels.
Safety studies push the boundaries of what’s tolerable. Animal testing showed that acute exposure to large Nefiracetam doses causes minimal lasting organ damage at therapeutic levels, though symptoms like agitation and tremor appear on higher exposure. Chronic studies highlighted the need to monitor liver enzymes and neurological status over time. Extended dosing sometimes leads to mild GI distress and changes in sleep patterns, but so far, irreversible toxicity appears unlikely at tested concentrations. A small number of clinical trials in humans found side effects mild to moderate, with no life-threatening reactions linked directly to Nefiracetam at doses under 900mg/day. Still, the substance's long-term effects in healthy adults remain a research gap, especially since recreational users often combine it with other racetams or supplements, risking unpredictable interactions.
Out on the horizon, Nefiracetam sits at a crossroads. Newer racetam derivatives claim sharper effects or cleaner metabolic profiles, yet few have the historical research footprint Nefiracetam does. The clinical need for cognitive enhancers only grows as populations live longer and chronic neurologic diseases increase. For Nefiracetam, future attention will likely pin to targeted therapy—possibly tailored to patients with specific neurotransmitter imbalances or as part of combination therapy for stroke rehabilitation. Regulatory trends point toward greater scrutiny, with new clinical trials demanding robust evidence before approving widespread use. Advances in delivery—like nanoparticle formulations or slow-release capsules—might push the compound into new roles. Still, any leap forward hangs on transparent publication of both benefits and risks, clear labeling, and a refusal to let hype outpace evidence. The story of Nefiracetam, like many chemicals born in the laboratory, remains unfinished and depends on marrying cautious optimism with hard data.
Stories about memory loss used to feel distant to me, something that mostly affected grandparents or movie characters. Then I watched a neighbor, who had always remembered every detail of my life, start to ask the same questions again and again. That’s when I started paying more attention to substances like nefiracetam. Developed in Japan during the late 80s, nefiracetam gained a following among researchers and people desperate to fight cognitive decline.
Unlike traditional prescription drugs for memory loss, nefiracetam finds its roots in the racetam family, which also produced popular names like piracetam. Its main appeal centers around the promise to sharpen focus, enhance recall, and help the brain form new connections. I read more stories of students and professionals taking supplements to fight “brain fog” and slow thinking. Nefiracetam often sits at the center of these debates because preliminary research links it to improvements in memory and learning in animals, especially rodents with chemically-induced memory trouble.
Dementia doesn’t just take away memories; it chips away at a sense of self. Some early trials and case reports hinted that nefiracetam could slow damage from Alzheimer’s or stroke-related memory problems. In one Japanese trial, people with post-stroke memory issues seemed to recall more daily events after taking nefiracetam. Animal studies back up some of these findings, showing increased acetylcholine release—a neurotransmitter tightly linked to focus and memory.
Many reports on nootropics ignore mental health, but nefiracetam finds mentions in research on anxiety and depression. Trials in animals showed reduced symptoms of anxiety, possibly through its influence on the body’s GABA system. Nefiracetam works differently from standard drugs, tweaking the way nerves send signals. This gives some hope to people who feel dulled or foggy from prescription medication, but real-world evidence for these uses in humans remains thin.
Access to nefiracetam mostly comes through internet shops and supplement vendors since it hasn’t received approval from drug regulators in the US or Europe. Health risk is hard to pin down with no long-term studies in large groups. I’ve read reports of headaches, nausea, and mood changes. Real, large-scale, controlled studies in humans haven’t caught up to the hype. So anyone thinking about using it should consult trusted medical professionals.
Nefiracetam sits on the line between hope and hype. Evidence from small studies and animal data keeps people curious, but plenty of questions still surround its long-term safety and real-world benefits. A strong safety record and clear results from human trials would help. For now, anyone drawn to these brain-boosting stories needs to weigh the appeal against the unknowns.
Instead of rolling the dice with promises from unregulated vendors, the best path means staying alert to new studies. Trusted research from places like PubMed or the NIH can separate trend from truth. Personally, I prefer putting my energy into better sleep, exercise, and food as a starting point for clearer thinking. Future research on nefiracetam still deserves our attention, but for now, we need to treat it with the caution reserved for substances on the cutting edge of medical science.
Nefiracetam has built a reputation among some people searching for cognitive boosts. It falls into the racetam family, and its popularity comes from academic circles and biohacking communities. Many folks get curious about the positive stories—sharper memory, clearer focus—but side effects often slip by without enough attention.
After following nootropics forums and reading academic papers, I keep seeing similar side effects in personal accounts. Some report headaches that feel like pressure, which could point to how the brain handles acetylcholine when someone takes racetams. I’ve read about digestive problems, too—nausea and diarrhea sometimes appear after a few days. No one wants to deal with gut discomfort in the middle of their work or study streak.
A few people mention agitation and anxiety. I’ve even seen folks abandon their experiments altogether because the anxious jitter became too much during stressful weeks. In some research settings, animal studies on nefiracetam have hinted at restlessness or changes in sleep, though human trials haven’t covered enough ground yet.
There’s one more thing that deserves the spotlight: the potential for liver stress and changes in kidney markers. People self-experimenting rarely order bloodwork, but documented cases from research in Japan raised questions. Nefiracetam can raise levels of certain enzymes, which are early signals that the liver’s under strain. These cases remain rare in the public, but it helps to approach new supplements with caution.
Drugs made for animals or restricted research uses don’t always translate well to long-term human safety. I remember a friend ordering nootropics online and struggling to pick dosage guidelines. Nefiracetam sits in that legal gray area in many countries. Some batches on the market might be impure or mislabeled, because supplements fall through regulatory cracks. It pays to remember that even a benign-looking nootropic can mix badly with other prescription drugs or supplements.
Older adults, people with kidney or liver issues, and those taking medication for epilepsy or depression face even more unknowns. The brain runs on a delicate balance, and tinkering with neurotransmitters can set off more problems than it fixes.
My own experience says that learning about new compounds works best when you hear both the upsides and the risk stories. Medical professionals stress the value of a conversation before anyone tries a substance like nefiracetam. Dosage, other medications, liver health—these are not boxes to skip.
One way to cut down risk involves regular medical checkups and open communication with a provider. I’ve learned more than once that chasing mental sharpness isn’t worth long-term health costs. For anyone feeling tempted by promises of nootropic magic, it helps to step back and weigh each side effect report against the quest for productivity. A sharper mind means little if the body pays a hidden price.
Plenty of people have questions about nootropics and their ability to sharpen thinking or improve memory. Nefiracetam, one of the less mainstream options from the racetam family, catches attention online for these reasons. Unlike older options like piracetam, nefiracetam brings a buzz about boosting cognition but also a lot of uncertainty around safe use. No prescription-grade guidelines exist for its use outside Japan. Even in places where nefiracetam remains accessible, people have to pull dosing guidance from scattered animal studies or early-stage human research. That makes me uneasy, not just as a writer but as someone who’s watched supplement trends cycle with more hope than care.
Most available dosing data comes from clinical trials in Japan on stroke recovery or Alzheimer’s, where adults usually received between 600-900 mg daily, split across two or three doses. Some open-label studies in different conditions used up to 1800 mg a day. These trials lasted for weeks or months and involved close physician monitoring. Without a doctor following bloodwork or checking for rare side effects, taking such amounts on your own becomes a risk. To make matters tougher, supplement purity varies widely. There’s no FDA oversight in most countries, leading to unreliable dosing with online-bought powder or capsules.
I remember how friends dove into the nootropic pool. Most wanted fast results, impatient to see focus sharpen or stubborn brain fog clear. Some experimented with doses anywhere between 200 to 1200 mg a day, split morning and afternoon. A few talked about headaches or stomach upset. Rare but real risks exist, given the way nefiracetam acts on brain chemistry—specifically, it modulates neurotransmitters like acetylcholine and GABA. Changing these brain pathways without guidance may backfire, especially if you already take medication or deal with mood issues. The possibility of liver strain or interactions creeps up the more people push their luck with new compounds.
It’s tempting to trust anecdotal reports over harder science, mostly because stories online feel relatable. Still, safety should take priority, especially for off-label cognitive enhancers. Nefiracetam isn’t cleared for long-term use outside Japan. The research remains spotty, with many questions around effects on mood, memory, and organ health. Anyone considering it for brain benefits would do better to start with the lowest amount possible—something under 200 mg per dose—rather than copying numbers from small clinical trials. It also pays to space doses twelve hours apart rather than bunching them together. No drug or supplement can “out-think” a poor night’s sleep or chronic stress, either. The real foundation comes from the basics: sleep, movement, and balanced meals. That’s an inconvenient truth for supplement enthusiasts but the most reliable path for brain health.
Whoever wishes to approach new cognitive enhancers like nefiracetam needs honest conversation with a health professional. Self-experimentation may spark insight but can’t replace the certainty of medical exams or expert observation. Bloodwork, mood scoring, and liver check-ins matter, especially with ongoing or higher doses. More transparency from supplement sellers would help, pressed by consumer interest and regulatory shifts in the future. Right now, the industry does not deliver consistent quality or clear risks. Advocating for tougher standards and demanding third-party testing remains a smart move for safety. People need more transparency—both about purity and about the long-term risks. Until more real-world data piles up, building brain health on safe, trusted routines will always beat chasing results from a mystery pill.
Nootropics catch a lot of attention these days, and nefiracetam has pulled in its fair share of fans hoping for sharper mental focus or better memory. I’ve seen plenty of people talking about it in online forums, often intrigued by early studies and anecdotes. The buzz makes sense, especially for anyone feeling worn down by stress or age and looking for a mental edge in daily life.
Step outside that hopeful talk, though, and things look more complicated. Nefiracetam hasn’t passed through the tough screenings laid out by the FDA in the United States. That’s a big deal for anyone considering it. Without official approval, pharmacies won’t carry it, and doctors steer clear of prescribing it. Other major regulatory groups, like the European Medicines Agency and Health Canada, also have not given nefiracetam a thumbs-up. These agencies demand rock-solid clinical trials proving both safety and benefits before greenlighting anything.
Some background helps: nefiracetam was originally studied in Japan for treating Alzheimer’s and stroke-related problems. Even there, enthusiasm faded. Trials raised questions about how well it actually works and whether risks outweigh any possible improvement in memory or focus. No major country has stepped in and given broad approval.
Conversations around nefiracetam safety pop up online all the time, mostly because the long-term side effects aren’t fully mapped out. Studies in animals raised a red flag about possible toxicity in the pancreas. There’s talk about risk for kidney and liver damage, especially with repeat or high dosing. Most researchers say there’s no reason to call it completely safe—at least, not until better data exists.
If someone chooses to buy nefiracetam, sources often end up being unregulated online shops. There’s no way to guarantee that the pill matches the label or hasn’t picked up a contaminant. I’ve seen enough stories about these pitfalls that I’d hesitate myself, even if I felt tempted by promised benefits.
Keeping brain health in check should never feel risky. Anyone tempted by supplements like nefiracetam can make life easier by talking to their doctor first. Sometimes curiosity and hope lead us towards products that feel like shortcuts, but sticking with substances fully examined by health regulators usually leads to better outcomes and fewer surprises. Anyone caught between curiosity and caution can look out for newer, trusted treatments for memory or focus, many of which have gone through detailed research and tough safety checks.
Reading up on unbiased, science-based sources helps cut through the hype. I’ve learned that chasing early research results gets tricky fast, especially when it comes to brain supplements. Strong evidence, supportive communities, and guidance from health pros make a big difference. Since nefiracetam hasn’t passed official safety and approval hurdles, avoiding it seems wiser for those who care about staying safe while seeking any cognitive edge.
People often turn to nootropics like nefiracetam, hoping for a mental edge or solutions to cognitive issues. This compound has roots in Japanese drug development, with some users swearing by its memory-boosting possibilities. With so much excitement, folks sometimes forget the less flashy part—what happens if you take it with other medications? Plenty of people mix supplements and prescriptions, but crossing signals can bring big risks.
Every pill or supplement we take goes through the liver. Enzymes like CYP450 break down drugs, but some substances can slow down or speed up these enzymes. When medications “compete” for these enzymes, the body gets unpredictable outcomes. I’ve seen folks tweak their regimen—adding something like nefiracetam—hoping to lift brain fog, but ending up fatigued or anxious. The catch? Many prescription drugs, from simple blood pressure meds to antidepressants, use the same enzyme systems as nootropics.
Research has shown that nootropics can interact with several medications. Nefiracetam carries some unique risks, especially since it tweaks neurotransmitters such as acetylcholine and GABA. If someone is already taking anti-anxiety medication, stacking nootropics can amplify side effects. In my own circle, friends who rely on antidepressants or anti-seizure drugs often ask about adding supplements. One friend mixed a choline supplement and a cognitive enhancer and landed in the ER with heart palpitations.
There’s plenty of data on rats, but real-world studies in humans lag behind. This lack of controlled studies leaves room for uncertainty, making personal trial-and-error more risky. With more medications on the market and more people seeking cognitive improvement, the pieces rarely fit nicely together.
Long-term drug users—folks managing conditions like epilepsy, bipolar disorder, or chronic anxiety—may be most vulnerable. Many anti-epileptic drugs alter neurotransmitter levels, and nootropics play in the same territory, sometimes pushing systems out of balance.
A candid conversation with a healthcare provider goes a long way. Doctors get nervous when patients pull out an unknown bottle. Over-the-counter “brain boosters” sound harmless, but missing details about a person’s prescription list can trigger harmful events.
According to the FDA, any supplement that influences neurotransmitter activity can pose an unpredictable risk when mixed with psychiatric drugs. Safety agencies worldwide recommend tracking every pill—prescribed, herbal, or purchased online—especially for people combining more than one drug.
Fixing this problem starts with easing up on do-it-yourself medicine. Seeking out pharmacists and clinicians who understand supplement interactions is worth the time. Community pharmacists often have drug interaction checkers, along with real-world stories about what mixtures have gone wrong.
The path forward includes stronger education and transparency. Clear labeling, better clinical trials, and frank advice from the medical community help steer people away from disaster. Most important, listening to your own body—being mindful when you layer new substances—makes for a smarter approach to brain health. Combining transparency with hard-won wisdom can help prevent harm, support real learning, and cultivate trust with caregivers and families.
| Names | |
| Other names |
DM-9384 DM 9384 N-(2,6-Dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)acetamide |
| Pronunciation | /ˌnɛfɪˈræsɪtæm/ |
| Identifiers | |
| CAS Number | 77191-36-7 |
| Beilstein Reference | 136072 |
| ChEBI | CHEBI:7528 |
| ChEMBL | CHEMBL32217 |
| ChemSpider | 126358 |
| DrugBank | DB05441 |
| ECHA InfoCard | 100.166.601 |
| EC Number | EC 255-791-4 |
| Gmelin Reference | 1091068 |
| KEGG | D01984 |
| MeSH | D019967 |
| PubChem CID | 4637 |
| RTECS number | UU7879000 |
| UNII | E2F4XMJ16P |
| UN number | UN3467 |
| Properties | |
| Chemical formula | C14H18N2O2 |
| Molar mass | 286.323 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | 1.278 g/cm³ |
| Solubility in water | slightly soluble |
| log P | 0.21 |
| Vapor pressure | 4.66E-12 mmHg at 25°C |
| Acidity (pKa) | 13.08 |
| Basicity (pKb) | 12.27 |
| Magnetic susceptibility (χ) | -74.0e-6 cm^3/mol |
| Refractive index (nD) | 1.577 |
| Dipole moment | 3.85 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 709.7 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -298.7 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -5333.2 kJ/mol |
| Pharmacology | |
| ATC code | N06BX07 |
| Hazards | |
| Main hazards | May cause skin and eye irritation. |
| GHS labelling | GHS05, GHS07 |
| Pictograms | GHS06, GHS08 |
| Signal word | No signal word |
| Hazard statements | No hazard statements. |
| Precautionary statements | IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
| NFPA 704 (fire diamond) | Health: 2, Flammability: 1, Instability: 0, Special: - |
| Flash point | 137.5 °C |
| Autoignition temperature | Autoignition temperature: 400°C |
| Lethal dose or concentration | LD50 (Mouse, oral): 4470 mg/kg |
| LD50 (median dose) | LD50 (median dose): 2000 mg/kg (oral, rat) |
| NIOSH | N06BX11 |
| PEL (Permissible) | Not Established |
| REL (Recommended) | 600-900 mg/day |
| Related compounds | |
| Related compounds |
Aniracetam Brivaracetam Dimiracetam Ethiracetam Fasoracetam Levetiracetam N-Desmethylnefiracetam Phenylpiracetam Piracetam Pramiracetam |
